TD Cowen on United Therapeutics (UTHR): Management Sees Blockbuster Potential as Ralinepag Succeeds

TD Cowen analyst Joseph Thome reiterated a Buy rating and $575.00 price target on United Therapeutics Corp. (NASDAQ: UTHR).

The analyst commented: "Ralinepag Succeeds In Outcomes Study; Management Sees Blockbuster Potential; UTHR reported positive results from the Ph. III study of ralinepag in PAH, which reduced the risk of clinical worsening by 55% compared to pbo. We see these results as impressive given the more heavily pre-treated pt pop in the study, and expect ralinepag to see solid uptake in PAH pts. We currently model $550MM in 2034 sales for ralinepag, though this could prove conservative given mgmt fireside."

For an analyst ratings summary and ratings history on United Therapeutics Corp. click here. For more ratings news on United Therapeutics Corp. click here.

Shares of United Therapeutics Corp. closed at $513.82 yesterday.

You May Also Be Interested In

• Northland Upgrades Similarweb Ltd (SMWB) to Outperform
• Goldman Sachs to acquire Neos in $2.3B deal
• Agencia Comercial Spirits signs $10M networking deal in Indonesia